Seminars & Webinars
2023
Event: Cell and Gene Therapy Insights Webinar
Date: July 26, 2023
Presenter: Andreja Gramc Livk, Sartorius BIA Separations
Adeno-associated viruses (AAVs) are widely used vectors for gene therapies mainly due to their favorable safety profile and high transduction efficiency to various target tissues. With increasing demand for faster process development of advanced therapies using AAVs, rapid at-line analytical chromatographic solutions are becoming indispensable.
PATfix analytical system with multiple detectors seamlessly delivers coherent process information, considerably speeding up process development and enabling a fast-paced delivery of the product to the market.
Analytical methods, embedded in the PATfix system that enables at-line monitoring of common product and process related impurities, provide a critical platform for the rapid development and characterization of AAV-based gene therapy vectors.
Event: Cell and Gene Therapy Insights webinar
Date: April 5, 2023
Presenter: Rok Žigon, Head of Product-Application Area (AAV/Adeno), Process Development Viruses
Adeno-associated virus (AAV) is go-to vector for gene therapy treatments. In each AAV downstream process, one of the key and often a bottleneck step is enrichment of full capsids. Along with scalability and capsid’s separation challenges one must account for sample heterogeneity and asses which analytics are adequate to distinguish between AAV sub-populations to deliver only the potent AAV product.
Chromatography on monolith columns offers efficient and scalable downstream processes. Case study using Design-of-experiment approach of buffer selection and robust preparation for improved separation of empty and full capsids will be presented along with paramount considerations for scaling up. In addition, residual host cell proteins, host cell DNA, plasmid DNA, and endotoxin removal efficiency will be discussed.
2022
Speaker: Mojca Tajnik Sbaizero, Project Manager
rAAV downstream process using monoliths contains a series of steps that are mutually dependent. Therefore each step should be optimized for sufficient outcome. Standard 96-well design offers a great advantage for screening many samples and conditions. It supports small sample intake and process automatization. We will present example of multi-parallel screening of different mobile phases for rAAVcapture step using CIM SO3 0.05 mL Monolithic 96-well Plates. Optimization of capture step leads to increased process productivity and product purity, as well as improves later polishing step. High vector recovery and greater reduction of impurities were confirmed on preparative scale chromatography resulting in successful implementation of screening tools for process development optimization.
Event: LCGC Live Webcast
Date: March 17, 2022
Presenters:
Rok Zigon, Project Manager; Process Development Dept.
Blaz Goricar, Project Manager; Process Analytical Technology Dept.
Key learning points:
- Rapid downstream process of AAV using monoliths, with emphasis on PATfix analytical tools
- Orthogonal analytics are paramount for AAV characterization
- Integration using PATfix enables fast evaluation of empty-full ratio
Event: Cell and Gene Therapy Insights webinar
Date: February 17, 2022
Presenter: Ales Strancar, Managing Director
Key learning points:
- One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids.
- When the expression in the cell line results in less than 10% full capsid it is quite impossible to reach better than 90% full in the final product. It is therefore mandatory to optimise the USP to result in better empty/full ratio.
- This can be efficiently realised by using at-line PATfix to allow for analysis of the full and empty capsids ratio directly in the harvest.
- The residual empty capsids can be removed by polishing step using different anion exchange columns.
2021
Published: Cell & Gene Therapy Insights 2021; 7(12), 1661
Date: December 20, 2021
Presenter: Maja Leskovec, Head of Process Development Viruses (viral vectors and vaccines)
Watch the video or read the poster to learn:
- Importance of sample pretreatment before first chromatographic step
- Rapid downstream process of AAV with emphasis on chromatographic step of CIMmultus SO3 capture
- Three different ligands full enrichment of AAV
- Why orthogonal analytics is the key in downstream development and what are the options
Attachments
Presenter: Ivana Petrović Koshmak, PhD
Event: Late Stage Bioprocessing & Viral Vectors 2 11 November 2021
Date: November 3, 2021
Abstract:
Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.
One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids. The most efficient way is to design the USP to result in less than 10% of empty capsids. This can be realised by process optimisation using at-line PATfix analytics to allow for analysis of the full and empty capsids ratio during the virus expression.
Fast and reliable at-line analytical methods to allow for process optimisation USP and DSP, and assessing the purity of the final product using PATfix system will be presented.
Attachments
Published: Cell & Gene Therapy Insights 2021; 7(8), 1125
Date: October 4, 2021
Presenter: Hana Jug, Project Manager in process development for viral vectors and vaccines
Watch the video or read the poster to learn:
- Why downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing
- How an adenoviral vector purification platform using CIMmultus™ QA as the key purification step, secures a fast and robust process with better purity
- CIMmultus™ QA offers high capacity and high yields of adenovirus, results in cost reduction and overcomes raw material supply bottlenecks
Attachments
Presenter: Aleš Štrancar
Event: BPI and Cell & Gene Therapy Bioprocessing & Commercialization 2021
Date: September 28, 2021
Abstract:
Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.
One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids. The most efficient way is to design the USP to result in less than 10% of empty capsids. This can be realised by process optimisation using at-line biochromatography analytics to allow for analysis of the full and empty capsids ratio directly in the harvest.
The residual empty capsids can be further removed by polishing purification step using different anion exchange columns.
Fast and reliable at-line analytical methods to allow for process optimisation and assessing the purity of the final product using PATfix system will be presented.
Attachments
Presenter: Ivana Petrović Koshmak
Event: 2nd Annual Gene Therapy Analytical Development EU
Date: May 26, 2021
Abstract:
In-process analytics of vector capsid production is a critical optimization target in development of AAV-based gene therapy products. In this presentation we introduce a fast at-line HPLC based system that enables differentiation of vector capsid and empty capsid production in transfection mixtures. Case study results demonstrating the effects of different process variables on capsid production and assembly are shown and insights about purification are also discussed.
Attachments
Presenter: Aleš Štrancar
Event: Genetic Vaccine Development for Infectious Diseases Summit
Date: May 20, 2021
Abstract:
- Developments in gene therapy and threat of pandemics requests novel technologies to allow for efficient manufacturing of very large biomolecules and nanoparticles within short time.
- Convective Interaction Media with open channel structures resulting in no shear forces allows for fast and very efficient manufacturing of mRNA, pDNA, Adeno and other VLP based Covid vaccines.
- Ultra-sensitive DNA assay and fast in-process control using PATfix systems are introduced for production of safer Covid vaccines.
Attachments
Presenter: Aleš Štrancar
Event: ASGCT 24th Annual Meeting
Date: May 13, 2021
Abstract
Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.
Therapeutic applications of AAV-based gene therapy vectors require the process and product related impurities to be removed, as they represent serious safety threats as well as burden the economics of manufacturing.
Attachments
2020
Presenter: Aleš Štrancar
Date: October 27, 2020
Gene Therapy for Rare Disorders Europe 2020 (digital event)
Bullet points:
- Buffer optimisation and proper column ligand selection (CIM QA, CIM PrimaS or new CIM EF) allows for >90% full capsid production
- Introduction of Specimen allows for production columns checking before use
- Using ultracentrifuge with set of HPLC detectors allows for prompt orthogonal verification of the full capsid purity
Attachments
2019
Presenter: Ales Strancar
Date: 20th of November 2019
Place: Boston, MA (Gene Therapy Analytical Development Summit)
Attachments
Presenter: Ales Strancar
Date: 19th of June 2019
Place: Biomanufacturing Training & Education Center (BTEC) in North Carolina